EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Outcome of bleomycin electrosclerotherapy of slow-flow malformations in adults and children

Vanessa F Schmidt, Özlem Cangir, Lutz Meyer, Constantin Goldann, Susanne Hengst, Richard Brill, Susanne von der Heydt, Milton Waner, Daniel Puhr-Westerheide, Osman Öcal, Muzaffer Reha Ümütlü, Nabeel Mansour und 8 weitere

European Radiology · 2024

DOI: 10.1007/s00330-024-10723-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Radiology, 2024. Verfasst von Vanessa F Schmidt und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, LMU University Hospital, LMU Munich, München, Germany. Vanessa.Schmidt@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Bleomycin. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the safety and clinical outcome of bleomycin electrosclerotherapy (BEST) for treating extracranial slow-flow malformations.

Methods

In this retrospective investigation of a multicenter cohort presenting symptomatic slow-flow malformations, patient records were analyzed with respect to procedural details and complications. A treatment-specific, patient-reported questionnaire was additionally evaluated, obtained 3–12 months after the last treatment, to assess the subjective outcomes, including mobility, aesthetic aspects, and pain, as well as the occurrence of postprocedural skin hyperpigmentation. All outcome parameters were compared according to patients’ age.

Results

Overall, 325 BEST treatments were performed in 233 patients after intralesional and/or intravenous bleomycin injection. The total complication rate was 10.2% (33/325), including 29/352 (8.9%) major complications. Patient-reported mobility decreased in 10/133 (8.8%), was stable in 30/113 (26.5%), improved in 48/113 (42.5%), and was rated symptom-free in 25/113 (22.1%) patients. Aesthetic aspects were rated impaired compared to baseline in 19/113 (16.8%), stable in 21/133 (18.6%), improved in 62/113 (54.9%), and perfect in 11/133 (9.7%) patients. Postprocedural skin hyperpigmentation occurred in 78/113 (69%) patients, remaining unchanged in 24/78 (30.8%), reduced in 51/78 (65.5%), and completely resolved in 3/78 (3.8%) patients. The median VAS pain scale was 4.0 (0–10) preprocedural and 2.0 (0–9) postprocedural. Children/adolescents performed significantly better in all parameters compared to adults (≥ 16 years) (mobility, p = 0.011; aesthetic aspects, p < 0.001; pain, p < 0.001).

Conclusions

BEST is effective for treating slow-flow vascular malformations, with few but potentially significant major complications. Regarding patient-reported outcomes, children seem to benefit better compared to older patients, suggesting that BEST should not be restricted to adults. Clinical relevance statement Bleomycin electrosclerotherapy is a safe and effective approach and therapy should not be restricted to adults due to good clinical outcomes in children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BleomycinHumansFemaleMaleChildRetrospective StudiesAdultAdolescentTreatment OutcomeChild, PreschoolMiddle AgedYoung AdultSclerotherapyInfantAgedAntibiotics, AntineoplasticElectrochemotherapy

Stichwörter der Autor:innen

BESTBleomycinElectro-chemotherapySclerotherapySlow-flow vascular malformations

Substanzen

BleomycinAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Department of Radiology, LMU University Hospital, LMU Munich, München, Germany. Vanessa.Schmidt@med.uni-muenchen.de.
  • Interdisziplinäres Zentrum für Gefäßanomalien (IZGA), LMU University Hospital, LMU Munich, München, Germany. Vanessa.Schmidt@med.uni-muenchen.de.
  • Department of Pediatric Surgery, Center for Vascular Malformations, Klinikum Barnim GmbH, Werner Forssmann Hospital, Eberswalde, Germany.
  • Clinic and Policlinic of Radiology, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
  • Department of Radiology, Center for Vascular Malformations, Klinikum Barnim GmbH, Werner Forssmann Hospital, Eberswalde, Germany.
  • Vascular Birthmark Institute of New York, New York, NY, USA.

Zitieren

APA

Schmidt, V. F., Cangir, Ö., Meyer, L., Goldann, C., Hengst, S., Brill, R., von der Heydt, S., Waner, M., Puhr-Westerheide, D., Öcal, O., Ümütlü, M. R., Mansour, N., Rudolph, J., Sint, A., Obereisenbuchner, F., Häberle, B., Ricke, J., Seidensticker, M., Wohlgemuth, W. A., & Wildgruber, M. (2024). Outcome of bleomycin electrosclerotherapy of slow-flow malformations in adults and children. European Radiology. https://doi.org/10.1007/s00330-024-10723-6

Vancouver

Schmidt VF, Cangir Ö, Meyer L, Goldann C, Hengst S, Brill R, et al. Outcome of bleomycin electrosclerotherapy of slow-flow malformations in adults and children. European Radiology. 2024. doi:10.1007/s00330-024-10723-6

BibTeX
@article{Schmidt2024,
  author = {Schmidt, Vanessa F and Cangir, Özlem and Meyer, Lutz and Goldann, Constantin and Hengst, Susanne and Brill, Richard and von der Heydt, Susanne and Waner, Milton and Puhr-Westerheide, Daniel and Öcal, Osman and Ümütlü, Muzaffer Reha and Mansour, Nabeel and Rudolph, Jan and Sint, Alena and Obereisenbuchner, Florian and Häberle, Beate and Ricke, Jens and Seidensticker, Max and Wohlgemuth, Walter A and Wildgruber, Moritz},
  title = {Outcome of bleomycin electrosclerotherapy of slow-flow malformations in adults and children},
  journal = {European Radiology},
  year = {2024},
  doi = {10.1007/s00330-024-10723-6}
}
Kostenlos starten →